Bioregulators

The family should not be treated as a single evidence tier. Epitalon is the best-supported member, with telomerase activation findings and a 2025 independent replication at Brunel University in London. Cartalax has in-vitro fibroblast and kidney-cell data but no human trials. Testagen sits at the bottom with one in-vitro DNA-binding study and no reproductive data. Anyone evaluating a specific bioregulator should check that compound's own evidence rather than relying on the reputation of the class.

The defining limitation of the entire bioregulator class is that essentially all of the supporting research originates from one Russian institute and one research group, largely published in Russian, with very little independent replication by outside laboratories. This mirrors the caveat already recorded in the knowledge base for Cartalax, where the mechanism is described as consistent and interesting but the evidence as early, narrow and not settled science.

Most Khavinson peptides are not FDA-approved for human use. They circulate as research compounds sold as not for human consumption, or occasionally as compounded preparations. This applies across the family including Testagen, Vilon, Livagen, Vesugen and Chonluten.

Members are defined by sequence and target organ. Vilon (Lys-Glu, dipeptide) targets thymus and immune function. Livagen (Lys-Glu-Asp-Ala, tetrapeptide) targets liver. Vesugen (Lys-Glu-Asp, tripeptide) targets vascular wall and blood vessels. Chonluten (Glu-Asp-Gly, tripeptide) targets respiratory and lung tissue. Testagen (Lys-Glu-Asp-Gly, tetrapeptide) targets the reproductive system. Epitalon (Ala-Glu-Asp-Gly) targets the pineal gland, and Cartalax targets connective tissue.

Because these peptides are only 2 to 4 amino acids, they are small enough to pass into the cell nucleus and are proposed to interact directly with DNA, modulating gene expression at the epigenetic level rather than signalling from the cell surface like most peptides. This is the same mechanism already documented in the knowledge base for Cartalax, which shifts an aged cell back toward a younger gene-reading pattern without altering the DNA sequence itself.

The founding premise is that every organ produces its own tissue-specific short peptides which regulate that organ's gene expression, and that these decline with age. Supplementing the corresponding peptide is theorised to restore youthful function to that specific tissue. This is why the family is organised by target organ rather than by effect, and why each member is marketed for one system.

Peptide bioregulators are a class of very short peptides (2 to 4 amino acids) developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology over roughly four decades. The entire family originates from this single research programme, which is the central caveat for the whole class: the body of work has essentially one source and has not been broadly replicated by independent Western laboratories.